Theravance Biopharma Q3 2022: YUPELRI sales up 35% YoY; $1.1B TRELEGY deal closed; debt-free

Theravance Biopharma, Inc.

2022-Q3 EPS reported $11.66 revenue$36,697,000

Implied 35% share of YUPELRI net sales $18.7M, up 35% YoY; Viatris collaboration revenue $12.4M.
Closed TRELEGY royalty sale to Royalty Pharma for ~$1.1B upfront; gain of $1.14B; now debt-free with $486.8M cash.
Initiated $250M capital return; purchased GSK's 9.6M shares at $9.75/shr; Dutch tender up to $95M extended to Nov 17.
Operating expenses guidance: R&D $45-55M, SG&A $35-45M for FY2022 (excl. share-based comp and one-time costs).
Ampreloxetine Phase 3 study (CYPRESS) in MSA patients with nOH to start Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Theravance Biopharma, Inc. reported third quarter of 2022 results: revenue $12.5 million.

Period: third quarter of 2022
Revenue: $12.5 million
Result: reported results

Exact text from the filing

Revenue: Total revenue for the third quarter of 2022 was $12.5 million

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-115424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.